Drug
VIR-7831
VIR-7831 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
2
50%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
completed375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_1
AGILE (Early Phase Platform Trial for COVID-19)
NCT04746183
completedphase_3
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780281
completedphase_3
ACTIV-3: Therapeutics for Inpatients With COVID-19
NCT04501978
completedphase_2
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
NCT04634409
Clinical Trials (4)
Showing 4 of 4 trials
NCT04746183Phase 1
AGILE (Early Phase Platform Trial for COVID-19)
NCT05780281Phase 3
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT04501978Phase 3
ACTIV-3: Therapeutics for Inpatients With COVID-19
NCT04634409Phase 2
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4